Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction — SMART ONE

Metastatic Carcinoma Clinical Trial

Official title:
A Feasibility Study of Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma (SMART ONE)

Status Active, not recruiting

Clinical Trial Summary

This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney. Stereotactic ablative body radiation therapy (SABR) is a highly-focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04939246
Study type	Interventional
Source	Baptist Health South Florida
Contact
Status	Active, not recruiting
Phase	N/A
Start date	June 18, 2021
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02605811` - Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer	Phase 2
Terminated	`NCT02960282` - Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
Completed	`NCT01320241` - Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture	Phase 2
Completed	`NCT02192346` - α-TEA in Advanced Cancer	Phase 1
Completed	`NCT01469598` - Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer	Phase 2
Active, not recruiting	`NCT04376502` - Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.	N/A
Active, not recruiting	`NCT02730923` - Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)	Phase 1/Phase 2